321
Views
12
CrossRef citations to date
0
Altmetric
Brief Review

Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis

Pages 1553-1563 | Accepted 22 Mar 2010, Published online: 30 Apr 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Andreas Fontalis, Eustathios Kenanidis, Rafail Angelos Kotronias, Afroditi Papachristou, Panagiotis Anagnostis, Michael Potoupnis & Eleftherios Tsiridis. (2019) Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss. Expert Opinion on Pharmacotherapy 20:9, pages 1123-1134.
Read now
Hisaya Kawate & Ryoichi Takayanagi. (2011) Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. Clinical Interventions in Aging 6, pages 151-160.
Read now

Articles from other publishers (10)

Srinivasarao Yaragorla & Doma Arun. (2022) Arylation and Aryne Insertion into C-Acylimines: A Simple, Flexible, and Divergent Synthesis of C2-Aryl Indoles. The Journal of Organic Chemistry 87:21, pages 14250-14263.
Crossref
Jae Nam Yun, Hye‐Su Kan, Ji‐Sun Yeun, Jae‐Hoon Kim, Minyu Lee, Namsick Kim, Tae‐Young Oh, Seung‐Kwan Nam, Yoon Seok Choi, In Sun Kwon, Kwang Lae Hoe & Jang Hee Hong. (2021) Bioequivalence for a Fixed‐Dose Combination Formulation of Bazedoxifene and Cholecalciferol Compared With the Corresponding Single Entities Given Together. Clinical Pharmacology in Drug Development 10:8, pages 850-858.
Crossref
Gui‐Feng Liu, Zong‐Qiang Wang, Lin Liu, Bu‐Tian Zhang, Ying‐Ying Miao & Shao‐Nan Yu. (2018) A network meta‐analysis on the short‐term efficacy and adverse events of different anti‐osteoporosis drugs for the treatment of postmenopausal osteoporosis. Journal of Cellular Biochemistry 119:6, pages 4469-4481.
Crossref
Olivier Bruyère, Johann Detilleux, Arkadi Chines & Jean-Yves Reginster. (2012) Relationships Between Changes in Bone Mineral Density or Bone Turnover Markers and Vertebral Fracture Incidence in Patients Treated with Bazedoxifene. Calcified Tissue International 91:4, pages 244-249.
Crossref
Bradley T. Michalsen, Teshome B. Gherezghiher, Jaewoo Choi, R. Esala P. Chandrasena, Zhihui Qin, Gregory R. J. Thatcher & Judy L. Bolton. (2012) Selective Estrogen Receptor Modulator (SERM) Lasofoxifene Forms Reactive Quinones Similar to Estradiol. Chemical Research in Toxicology 25:7, pages 1472-1483.
Crossref
Teshome B. Gherezghiher, Bradley Michalsen, R. Esala P. Chandrasena, Zhihui Qin, Johann Sohn, Gregory R.J. Thatcher & Judy L. Bolton. (2012) The naphthol selective estrogen receptor modulator (SERM), LY2066948, is oxidized to an o-quinone analogous to the naphthol equine estrogen, equilenin. Chemico-Biological Interactions 196:1-2, pages 1-10.
Crossref
. (2011) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 18:6, pages 418-424.
Crossref
Péter Lakatos. (2011) Pharmacologic treatment of osteoporosis – 2011. Orvosi Hetilap 152:33, pages 1320-1326.
Crossref
David F. Archer. (2011) The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women. Menopause 18:1, pages 6-7.
Crossref
Santiago Palacios. (2010) Third generation SERMs: Anything new?. Maturitas 67:2, pages 101-102.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.